Proteinuria lowers the risk of amphotericin B-associated hypokalaemia

Journal of Antimicrobial Chemotherapy

Volumn 60, Issue 3, 2007, Pages 690-693

  Mohan, Sumit ^a,b   Ahmed, Saud ^a,b   Alimohammadi, Behzad ^a,b   Jaitly, Manasvi ^a,b   Cheng, Jen Tse ^a,b   Pogue, Velvie A ^a,b  

^a Division of Nephrology   (United States)

^b University College of Physicians and Surgeons ^*  (United States)

Author keywords

Antifungal therapy; Drug protein interaction; Electrolyte abnormalities; Nephrotoxicity; Protein binding; Tubular toxicity

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B DEOXYCHOLATE; ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; DIPHENHYDRAMINE; MAGNESIUM SULFATE; PARACETAMOL; POTASSIUM CHLORIDE; SODIUM CHLORIDE; STEROID;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG PROTEIN BINDING; FEMALE; HUMAN; HYPOKALEMIA; INCIDENCE; MALE; PROTEINURIA; RISK ASSESSMENT; RISK REDUCTION;

ADULT; AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; FEMALE; HUMANS; HYPOKALEMIA; KIDNEY DISEASES; MALE; MIDDLE AGED; MYCOSES; PROTEINURIA; RETROSPECTIVE STUDIES; RISK;

EID: 34548128390     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm220     Document Type: Article

References (16)

1. Gallis H, Drew R, Pickard W. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990; 12: 308-29.
2. Harbarth S, Pestotnik SL, Lloyd JF et al. The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy. Am J Med 2001; 111: 528-34.
3. Douglas J, Healy J. Nephrotoxic effects of amphotericin B, including renal tubular acidosis. Am J Med 1969; 46: 154-62.
4. Patterson R, Ackerman G. Renal tubular acidosis due to amphotericin B nephrotoxicity. Arch Intern Med 1971; 127: 241-4.
5. Barton C, Pahl M, Vaziri N et al. Renal magnesium wasting associated with amphotericin B tharapy. Am J Med 1984; 77: 471-4.
6. Sawaya B, Briggs J, Schnermann J. Amphotericin B nephrotoxicity: The adverse consequences of altered membrane. J Am Soc Nephrol 1995; 6: 154-64.
7. Steinmetz P, Lawson L. Defect in urinary acidification induced in vitro by amphotericin B. J Clin Invest 1970; 49: 596-601.
8. Tasset C, Preat V, Bernard A et al. Comparison of nephrotoxicities. of different polyoxyethyleneglycol formulations of amphotericin B in rats. Antimicrob Agents Chemother 1992; 36 1525-31.
9. Deray G. Amphotericin B nephrotoxicity. J Antimicrob Chemother 2002; 49: 37-41.
10. Chang J, Witty R, Robinson R et al. Amphotericin B nephrotoxicity: increased renal resistance and tubule permeability. Kidney Int 1982; 22: 626-3.
11. Sawaya B, Weihprecht H, Campbell W et al. Direct vasoconstriction as a possible cause for amphotericin B-induosd nephrotoxicity in rats. J Clin Invest 1991; 87: 2097-107.
12. Lichtenstein NA. Effect of amphotericin B on the permeability of the toad bladder. J Clin Invest 1965; 44: 1328-42.
13. Atkinson AJ, Bennett J. Amphotericin B pharmacokinetics in humans. Antimicrob Agents Chemother 1978; 13: 271-6.
14. Bekersky I, Fielding R, Dressler D et al. Pharmacokinetics excretion mass balance of liposomal amphotericin B (AmBisome) amphotericin B deoxycholate in humans. Antimicrob Agents Chemother 2002; 46: 828-33.
15. Bekersky I, Fielding RM, Dressler DE et al. Plasma protein binding of amphotercin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrob Agents Chemother 2002; 46: 834-40.
16. Romanini D, Avalle G, Farruggia B et al. Spectroscopy features of the binding of polyene antibiotics to human serum albumin. Chem Biol Interact 1998; 115: 247-60.